Asunto(s)
Donantes de Sangre , Virus de la Hepatitis E/aislamiento & purificación , Hepatitis E/diagnóstico , Ensayo de Inmunoadsorción Enzimática/métodos , Anticuerpos Antihepatitis/sangre , Hepatitis E/sangre , Hepatitis E/epidemiología , Humanos , Italia/epidemiología , Estudios SeroepidemiológicosRESUMEN
This study was aimed at assessing the anti-HBs persistence and immune memory 18-19 y after vaccination against hepatitis B in healthy individuals primed as infants or adolescents. We enrolled 405 teenagers (Group A) vaccinated as infants, and 409 young adults (Group B) vaccinated as adolescents. All vaccinees were tested for anti-HBs and anti-HBc antibodies; those found anti-HBc positive were further tested for HBsAg and HBV DNA. Eight individuals belonging to Group B were positive for anti-HBc alone, and were excluded from analysis. Individuals with anti-HBs concentration ≥ 10 mIU/ml were considered protected while those with anti-HBs concentration <10 mIU/ml were offered a booster dose and re-tested 2 weeks later. Overall, 67.9% individuals showed anti-HBs concentrations ≥ 10 mIU/ml (48.9% in Group A vs 87.0% in Group B, p < 0.001). The antibody geometric mean concentration (GMC) was higher in Group B than in Group A (102.5 mIU/ml vs 6.9 mIU/ml; p < 0.001). When boosted, 94.2% of vaccinees with anti-HBs <10 mIU/ml belonging to Group A and 94.7% to Group B showed an anamnestic response. Post-booster GMCs were similar in both groups (477.9 mIU/ml for Group A vs 710.0 mIU/ml for Group B, p = n.s.). Strong immunological memory persists for at least 18-19 y after immunization of infants or adolescents with a primary course of vaccination. Thus, booster doses are not needed at this time, but additional follow up is required to assess the long-life longevity of protection.
Asunto(s)
Anticuerpos contra la Hepatitis B/sangre , Vacunas contra Hepatitis B/inmunología , Hepatitis B/prevención & control , Inmunización Secundaria , Memoria Inmunológica , Adolescente , Adulto , Femenino , Hepatitis B/epidemiología , Hepatitis B/inmunología , Vacunas contra Hepatitis B/administración & dosificación , Humanos , Lactante , Italia/epidemiología , Masculino , Factores de Tiempo , Adulto JovenRESUMEN
BACKGROUND: A prospective, 1-year study was performed among Italian first-time, volunteer blood donors, who account for 12% of all donations, in order to assess the frequency and serological patterns of hepatitis B virus infection and the presence of occult infection. MATERIALS AND METHODS: Consecutive donors (n=31,190) from 21 blood transfusion centres, from age classes not subjected to universal HBV vaccination, were tested for HBsAg and anti-HBc by commercial immunoassays. Other HBV serological markers were searched for and qualitative and quantitative assessments of HBV-DNA were made in HBsAg and/or anti-HBc-positive individuals. RESULTS: Of the 31,190 donors studied, 100 (0.32%) were positive for both HBsAg and anti-HBc, 2 for HBsAg (0.01%) alone, and 2,593 (8.3%) for anti-HBc. Of these last, 86.7% were also positive for anti-HBs (with or without anti-HBe), 2.9% were positive for anti-HBe without anti-HBs and 10.4% had no other HBV markers (anti-HBc alone). A general north-south increasing gradient of HBV prevalence was observed. Circulating HBV-DNA was found in 96.8% of HBsAg-positive subjects as compared to 0.55% (12/2,186) of anti-HBc-positive/HBsAg-negative subjects, with higher frequencies among anti-HBs-negative than among anti-HBs-positive ones (1.68% vs. 0.37%; p <0.01) and among the 57 cases positive for both anti-HBc and anti-HBe (7%). HBV-DNA levels were significantly higher in HBsAg-positive subjects than in HBsAg-negative ones (median: 456 IU/mL vs. 38 IU/mL). CONCLUSIONS: The prevalence of HBV infection among Italian first-time blood donors is much lower than in the past. The presence of occult infections in this group was confirmed (frequency: 1 in 2,599), supporting the hypothesis of long-term persistence of HBV infection after clearance of HBsAg. HBsAg and nucleic acid amplification testing for blood screening and vaccination against HBV are crucial in order to further reduce the risk of transfusion-transmitted HBV towards zero.
Asunto(s)
Donantes de Sangre , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis B/diagnóstico , Hepatitis B/epidemiología , Adulto , Sangre/virología , Seguridad de la Sangre , ADN Viral/sangre , ADN Viral/aislamiento & purificación , Femenino , Hepatitis B/transmisión , Antígenos del Núcleo de la Hepatitis B/sangre , Antígenos del Núcleo de la Hepatitis B/aislamiento & purificación , Antígenos de Superficie de la Hepatitis B/sangre , Antígenos de Superficie de la Hepatitis B/aislamiento & purificación , Humanos , Italia/epidemiología , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Nucleic acid testing (NAT) for hepatitis C virus (HCV) and human immunodeficiency virus (HIV) has been implemented in several European countries and in the United States, while hepatitis B virus (HBV) NAT is still being questioned by opinions both in favor and against such an option, depending on the HBV endemicity, health care resources, and expected benefits. STUDY DESIGN AND METHODS: This survey was aimed to assess the NAT impact in improving the safety of blood supply in Italy, 6 years after implementation. The study involved 93 Italian transfusion centers and was carried out in 2001 through 2006. A total of 10,776,288 units were tested for the presence of HCV RNA, 7,932,430 for HIV RNA, and 3,405,497 for HBV DNA, respectively. RESULTS: Twenty-seven donations or 2.5 per million tested were HCV RNA-positive/anti-HCV-negative; 14 or 1.8 per million units tested were HIV RNA-positive/anti-HIV-negative; and 197 or 57.8 per million donations tested were HBV DNA-positive/hepatitis B surface antigen-negative. Of the latter, 8 (2.3/10(6)) were collected from donors in the window phase of infection and 189 (55.5/10(6)) from donors with occult HBV. Sixty-eight percent of the latter donors had hepatitis B surface antibody, 74.5 percent of whom with concentrations considered protective (>or=10 mIU/mL). CONCLUSION: NAT implementation has improved blood safety by reducing the risk of entering 2.5 HCV and 1.8 HIV infectious units per million donations into the blood supply. The yield of NAT in detecting infectious blood before transfusion was higher for HBV than for HCV or HIV. However, the benefit of HBV NAT in terms of avoided HBV-related morbidity and mortality in blood recipients needs to be further evaluated.
Asunto(s)
Bancos de Sangre/estadística & datos numéricos , Bancos de Sangre/normas , Donantes de Sangre , Seguridad , Virosis , Adulto , Anciano , Femenino , Genotipo , VIH/genética , VIH/aislamiento & purificación , Infecciones por VIH/sangre , Infecciones por VIH/epidemiología , Infecciones por VIH/transmisión , Encuestas de Atención de la Salud , Hepacivirus/genética , Hepacivirus/aislamiento & purificación , Hepatitis B/sangre , Hepatitis B/epidemiología , Hepatitis B/transmisión , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis C/sangre , Hepatitis C/epidemiología , Hepatitis C/transmisión , Humanos , Italia , Masculino , Tamizaje Masivo/normas , Tamizaje Masivo/estadística & datos numéricos , Persona de Mediana Edad , Morbilidad , Factores de Riesgo , Conducta de Reducción del Riesgo , Estudios Seroepidemiológicos , Virosis/sangre , Virosis/epidemiología , Virosis/transmisiónRESUMEN
We evaluated the COBAS Ampliscreen hepatitis B virus (HBV) test using standards, seroconversion panels, consecutive donations, and samples from patients with abnormal alanine aminotransferase and chronic hepatitis C. Specificity was 100% and sensitivity was 20 IU/ml. In seroconversion panels, HBV DNA was detected up to 4 to 18 days before HBsAg, suggesting that this assay is useful in shortening the infectious window phase.